Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genedata Expressionist® Established as Data Analysis Platform for Oncological Research

Published: Friday, December 28, 2012
Last Updated: Friday, December 28, 2012
Bookmark and Share
carcinoGENOMICS and other EU-funded research consortia help Genedata advance software platform

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has announced its successful contributions to several oncology-related research consortia, including the EU-funded carcinoGENOMICS, Newgeneris, and INCA projects. Genedata Expressionist, the company's flagship product for molecular profiling applications, was successfully used by these consortia for the analysis and management of complex high-volume, oncology-related data. Additionally, the consortia's oncology-specific requirements fueled the development of enhanced capabilities in Genedata Expressionist, which are now available to all licensees of the software. A comprehensive and enterprise-level solution, Genedata Expressionist helps to identify and understand molecular biomarkers by easily integrating transcriptomics, genomics, epigenomics, proteomics, and metabolomics data.

In implementing Genedata Expressionist for Genomic Profiling, Genedata domain experts worked closely with several EU research consortia including the carcinoGENOMICS project. carcinoGENOMICS was comprised of 20  research organizations representing the pharmaceutical industry as well as leading academic institutions from across Europe. The consortium developed a series of in vitro tests representative of various modes of carcinogenic action for the major target organs liver, lung, and kidney. This approach enables efficient assessment of a high number of compounds as required under  REACH, the European Community Regulations on chemicals and their safe use.  Moreover, this testing resulted in best practices required to successfully reduce animal testing while enabling more cost-efficient R&D processes.

"Toxicogenomics  research is generating large amounts of complex omics data and researchers are challenged to make sense of these data," noted Prof. Dr. Jos Kleinjans, scientific director of the Netherlands Toxigenomic Centre, who  is the coordinator  of the carcinoGENOMICS Project. "Genedata Expressionist helps researchers to effectively meet these challenges, by efficiently analyzing high-throughput molecular profiling data" continued Kleinjans. "Moreover, the Genedata team of scientists provides the necessary expertise to ensure the success of ambitious projects such as ours."

Researchers use Genedata Expressionist to assess assay reproducibility and predict compound carcinogenicity. Assays are based on the application of omics technologies (i.e. genome-wide transcriptomics and metabolomics) to robust in vitro systems (rat/human). Phenotypic markers for genotoxic and carcinogenic events are assessed to anchor gene expression modulations, metabolic profiles, and mechanistic pathways. Through extensive biostatistics, literature mining, and analysis of molecular-expression datasets, differential genetic pathways are identified, which are capable of predicting mechanisms of chemical carcinogenesis in vivo. Furthermore, Genedata Expressionist is able to integrate transcriptomics and metabolomics data to provide a holistic understanding of systems biology and build an iterative in silico model of chemical carcinogenesis.

Recently, Genedata also contributed its software solutions to a number of innovative EU-funded, oncology-focused projects, including:

*    NewGeneris - the consortium successfully investigated chemical risks concerning the development of childhood cancer and immune disorders and the role of prenatal exposure to genotoxic chemicals through maternal intake of  food during pregnancy.
 
*    INCA - the consortium successfully examined the role of chronic viral infections in the development of cancer.

"Genedata is proud to work with some of the  leading scientists and research organizations worldwide who are  fighting some of the most life-threatening diseases," said Dr. Othmar Pfannes, CEO of Genedata. "The know-how and experience gathered in such collaborations continues to drive the advancement of Genedata Expressionist - with the enhancements now available to all licensees of the system."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genedata Announces Evotec Selects Genedata Screener
Company has announced that Evotec has selected Genedata Screener® as a data management platform solution for its drug discovery research.
Wednesday, June 29, 2016
Boehringer Ingelheim Chooses Genedata Selector for Cell Line Development and Cell Culture Optimization
Company has announced that the leading pharma company to implement Genedata Selector as its global cell line and genome knowledge management platform.
Thursday, March 10, 2016
Genedata Signs License Agreement with AstraZeneca
Genedata Screener now AstraZeneca’s corporate platform for expediting drug discovery.
Saturday, November 21, 2015
Kymab Implements Genedata Biologics for High-throughput Antibody Discovery
Genedata Biologics™ integrated workflow platform used to increase throughput and automation of Kymab’s transgenic mice-based discovery platforms.
Tuesday, November 17, 2015
Genedata Completes Important Milestone in Collaboration with Bayer Pharma AG
Successful integration of Genedata Profiler™ allows researchers to access, process, analyze and manage petabytes of NGS and other omics data from patients and pre-clinical experiments.
Thursday, September 24, 2015
Merck Serono Chooses Genedata Biologics to Streamline Antibody Discovery Processes
Global deployment of Genedata Biologics across multiple protein therapeutics R&D groups to standardize workflows and improve efficiency.
Thursday, July 23, 2015
Genedata Releases a Breakthrough for Genomic Comparison
Genedata Selector™4.0 provides reference-independent genome sequence comparisons while reducing data processing and analysis time to optimize efficiency and save costs.
Wednesday, July 22, 2015
Genedata Forges Alliance with Intellicyt
Swiss informatics firm Genedata and Intellicyt today announced an alliance to work on cell-based screening in drug discovery.
Thursday, June 18, 2015
Precision Medicine Software Genedata Profiler™ Launched at Bio-IT World
Open, interoperable enterprise platform for patient and compound profiling provides important data management infrastructure for pharma internal R&D processes.
Friday, April 24, 2015
Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata, Bayer Pharma AG Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata Biologics Licensed by Pfizer
Pfizer implements Genedata Biologics to streamline global biopharma R&D processes.
Wednesday, March 04, 2015
Boehringer Ingelheim Selects Genedata Biologics as Antibody Discovery Workflow Platform
Genedata Biologics integrates and streamlines workflows for protein therapeutics R&D groups across multiple Boehringer Ingelheim sites.
Thursday, February 19, 2015
Genedata Highlights Combination Screening and Surface Plasmon Resonance at SLAS 2015
Colloquium and tutorials on Combination Screening and SPR examine Genedata Screener as the platform for all plate-based screening experiments.
Wednesday, February 04, 2015
Takara Bio Selects Genedata Software to Automate and Standardize NGS Data Analysis
Genedata Expressionist® for Genomic Profiling helps Takara Bio to manage, process, and analyze large NGS datasets.
Wednesday, November 05, 2014
Scientific News
Shedding Light on HIV Vaccine Design
Broadly speaking - Mathematical modelling of host-pathogen coevolution sheds light on HIV vaccine design.
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Automated Patch Clamping Trends
Learn more about current practices, preferences and metrics in ion channel drug screening using APC technology.
Lab-on-a-Stick: Miniaturised Clinical Testing For Fast Detection Of Antibiotic Resistance
A portable power-free test for the rapid detection of bacterial resistance to antibiotics has been developed by academics at Loughborough University and the University of Reading.
Genetic Ancestry of Cultivated Strawberry Unravelled
UNH scientists constructed a linkage map of the seven chromosomes of the diploid Fragaria iinumae, which allows them to fill in a piece of the genetic puzzle about the eight sets of chromosomes of the cultivated strawberry.
Progress In Vaccination Against Vespid Venom
Researchers at the Helmholtz Zentrum München and the Technical University Munich have presented a method which facilitates a personalised procedure for wasp allergy sufferers.
New Drug Target for Inflammatory Disorders
Penn study finds enigmatic molecules maintain equilibrium between fighting infection and inflammatory havoc.
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Mechanisms of Calcium Blockers
Researchers describe how the fundamental mode of action of two distinct chemical classes of calcium channel blockers differs.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!